41O - A Phase I Study of CPI-0610, a Bromodomain and Extra Terminal Protein (BET) Inhibitor in Patients with Relapsed or Refractory Lymphoma

Date 06 March 2018
Event TAT 2018 - Targeted Anticancer Therapies
Session Proffered Paper Session 2
Topics Anti-Cancer Agents & Biologic Therapy
Haematologic Malignancies
Presenter Adrian Senderowicz
Citation Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048
Authors K.A. Blum1, J. Abramson2, M. Maris3, I. Flinn4, A. Goy5, J. Mertz6, R. Sims6, F. Garner6, A. Senderowicz7, A. Younes8
  • 1Emory University Winship Cancer Institute, B3233 - Atlanta/US
  • 2Massachusetts General Hospital Cancer Center, Cambridge/US
  • 3Colorado Blood Cancer Institute, Denver/US
  • 4Sarah Cannon Research Institute, Nashville/US
  • 5Hackensack University Medical Center, Hackensack/US
  • 6Constellation Pharmaceuticals, 02142 - Cambridge/US
  • 7Constellation Pharmaceuticals, Cambridge/US
  • 8Memorial Sloan-Kettering Cancer Center, 10065 - New York/US


NF-kB has been found to be constitutively activated in many lymphomas, such as diffuse large B-cell lymphomas (DLBCL), particularly the ABC subgroup. In preclinical studies, CPI-0610, a BET specific small molecule inhibitor, results in downregulation of NF-κB signaling activity, accompanied by loss of viability of ABC-DLBCL cell lines. Here we report the results from the first-in human Phase 1 study of CPI-0610 in patients with relapsed or refractory lymphomas (NCT01949883).